Progyny (PGNY) Competitors $23.13 +0.57 (+2.53%) Closing price 04:00 PM EasternExtended Trading$23.13 0.00 (0.00%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PGNY vs. GH, RDNT, OPCH, SHC, BTSG, WGS, SGRY, CON, PRVA, and VCYTShould you be buying Progyny stock or one of its competitors? The main competitors of Progyny include Guardant Health (GH), RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), GeneDx (WGS), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), and Veracyte (VCYT). These companies are all part of the "healthcare" industry. Progyny vs. Its Competitors Guardant Health RadNet Option Care Health Sotera Health BrightSpring Health Services GeneDx Surgery Partners Concentra Group Holdings Parent Privia Health Group Veracyte Progyny (NASDAQ:PGNY) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends. Which has more risk and volatility, PGNY or GH? Progyny has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Does the media favor PGNY or GH? In the previous week, Progyny had 4 more articles in the media than Guardant Health. MarketBeat recorded 13 mentions for Progyny and 9 mentions for Guardant Health. Guardant Health's average media sentiment score of 1.17 beat Progyny's score of 1.06 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Guardant Health 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of PGNY or GH? 94.9% of Progyny shares are held by institutional investors. Comparatively, 92.6% of Guardant Health shares are held by institutional investors. 9.4% of Progyny shares are held by company insiders. Comparatively, 6.1% of Guardant Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is PGNY or GH more profitable? Progyny has a net margin of 4.28% compared to Guardant Health's net margin of -49.93%. Progyny's return on equity of 10.69% beat Guardant Health's return on equity.Company Net Margins Return on Equity Return on Assets Progyny4.28% 10.69% 7.12% Guardant Health -49.93%N/A -28.95% Which has higher valuation and earnings, PGNY or GH? Progyny has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProgyny$1.17B1.70$54.34M$0.5939.20Guardant Health$739.02M10.34-$436.37M-$3.35-18.29 Do analysts recommend PGNY or GH? Progyny presently has a consensus price target of $25.10, indicating a potential upside of 8.52%. Guardant Health has a consensus price target of $57.50, indicating a potential downside of 6.17%. Given Progyny's higher possible upside, analysts clearly believe Progyny is more favorable than Guardant Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Progyny 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.73Guardant Health 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 3.06 SummaryProgyny beats Guardant Health on 11 of the 16 factors compared between the two stocks. Get Progyny News Delivered to You Automatically Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGNY vs. The Competition Export to ExcelMetricProgynyMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.99B$7.66B$5.74B$9.56BDividend YieldN/A2.70%4.53%4.08%P/E Ratio39.2076.3830.4525.16Price / Sales1.7030.60392.5887.64Price / Cash65.8924.2337.0358.50Price / Book3.8616.818.956.21Net Income$54.34M$243.33M$3.26B$265.38M7 Day Performance2.57%-0.95%1.06%-1.13%1 Month Performance0.83%0.99%4.31%-0.71%1 Year Performance7.23%11.01%28.40%18.89% Progyny Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGNYProgyny2.3908 of 5 stars$23.13+2.5%$25.10+8.5%+7.1%$1.99B$1.17B39.20310News CoveragePositive NewsAnalyst ForecastGHGuardant Health3.0924 of 5 stars$54.80+1.1%$57.50+4.9%+111.3%$6.83B$739.02M-16.362,021Positive NewsRDNTRadNet3.2895 of 5 stars$62.00+16.2%$69.60+12.3%+10.3%$4.65B$1.87B-144.1811,021Analyst UpgradeInsider TradeHigh Trading VolumeOPCHOption Care Health4.6502 of 5 stars$27.85-1.2%$35.75+28.4%-12.3%$4.52B$5.00B22.288,088News CoveragePositive NewsSHCSotera Health1.2365 of 5 stars$14.06+0.6%$16.00+13.8%+9.4%$3.99B$1.11B175.773,000High Trading VolumeBTSGBrightSpring Health Services1.6615 of 5 stars$20.66-0.6%$25.67+24.2%+92.9%$3.66B$12.57B66.6535,000Positive NewsWGSGeneDx2.3527 of 5 stars$110.54+5.1%$101.63-8.1%+250.9%$3.15B$362.32M2,210.801,200SGRYSurgery Partners2.9361 of 5 stars$22.74-3.8%$33.00+45.1%-14.4%$2.92B$3.11B-15.9015,000CONConcentra Group Holdings Parent2.3727 of 5 stars$21.47-0.7%$28.50+32.7%-0.5%$2.75B$1.90B18.0411,250News CoveragePositive NewsPRVAPrivia Health Group4.2024 of 5 stars$20.31-1.3%$28.00+37.9%+6.8%$2.48B$1.90B184.651,140News CoveragePositive NewsAnalyst UpgradeVCYTVeracyte2.8089 of 5 stars$27.99+2.3%$40.90+46.1%-6.9%$2.20B$445.76M84.82790 Related Companies and Tools Related Companies Guardant Health Alternatives RadNet Alternatives Option Care Health Alternatives Sotera Health Alternatives BrightSpring Health Services Alternatives GeneDx Alternatives Surgery Partners Alternatives Concentra Group Holdings Parent Alternatives Privia Health Group Alternatives Veracyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PGNY) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progyny With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access